Acurx Pharmaceuticals Inc. (NASDAQ: ACXP) announced a registered direct offering that will provide $2.5 million in immediate proceeds, with the potential for up to $4.6 million more if warrants are exercised.

The biopharmaceutical company entered into an agreement to sell 825,085 shares of common stock at $3.03 per share. The offering includes concurrent private placement of short-term warrants to purchase up to 1,650,170 shares at an exercise price of $2.78 per share.

The warrants will be exercisable immediately upon issuance and expire 24 months after the registration statement becomes effective. H.C. Wainwright & Co. serves as the exclusive placement agent for the offering.

The closing is expected to occur on April 16, 2026, subject to customary conditions. Acurx stated it intends to use net proceeds for working capital and general corporate purposes.

The shares are being offered under a shelf registration statement filed with the Securities and Exchange Commission on July 9, 2025, which became effective January 6, 2026. The warrants are being issued through a private placement under Section 4(a)(2) of the Securities Act.

Acurx develops antibiotics for difficult-to-treat bacterial infections. The company's lead product candidate, ibezapolstat, targets C. difficile infections and is ready for Phase 3 trials pending financing.